A Study Assessing Rocatinlimab (AMG 451) Monotherapy in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Horizon)

Clinical trial NCT05651711 · COMPLETED

Trial details

NCT number: NCT05651711
Sponsor: Amgen
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Atopic Dermatitis

Start date: 2022-12-14
Primary completion: 2024-06-05
Enrollment: 726

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.